GT Molecular

GT Molecular is a private, commercial-stage diagnostics and services company leveraging its proprietary multiplex digital PCR platform to address needs in public health surveillance and cancer research. Its core business revolves around selling high-performance PCR assay kits for pathogens (e.g., Influenza, SARS-CoV-2) and cancer mutations (e.g., EGFR, KRAS), as well as providing rapid wastewater testing services for municipalities and other entities. The company has gained recognition through contracts like the CDC's NWSS Multi-Pathogen Assay Development award and was noted for early detection of SARS-CoV-2 variants in wastewater, positioning it at the intersection of molecular diagnostics and environmental monitoring.

Patented multiplex digital PCR (dPCR) and RT-qPCR technology (GT-Plex™) enabling ultra-sensitive, simultaneous detection of multiple nucleic acid targets from complex samples like wastewater and blood.

GT Molecular competes with large IVD companies like Thermo Fisher, Bio-Rad, QIAGEN, and Roche in the PCR assay space, and with specialized wastewater testing firms and academic labs in the surveillance sector. Its differentiation hinges on its claimed ultra-sensitivity, multiplexing capabilities, and rapid turnaround for testing services.